서브이미지

Our Pipeline

Pipeline

Our Programs

Reactive oxygen species (ROS), the fundamental cause of more than 90% of chronic disease, is unstable reactive oxygen species, which accumulation of excessive amount cause series of damages to human cells and ultimately organs. Humans are born with Superoxide Dismutase (SOD), an antioxidant enzyme that can defend against ROS, but amount and activity continually decrease as we age.

Genofocus is developing high-purity SOD, antioxidant enzyme, produced using microbial engineering & secreting expression technologies to develop SOD into therapeutic molecule. 4 Korea domestic patents and 1 US patent has been successfully registered. SOD producing strain is the first strain patent obtained in Korea, which has been developed as new drug to exert continuous antioxidant effect, removing ROS, to restore human homeostasis.

SOD-based pharmaceutical candidate substance.

GF-101 : Wild Type

  • Nutraceutical ingredients
    • Efficacy validation through clinical studies & new application exploration

GF-103 : Mutant

  • High-purity therapeutic protein
    • Global clinical trials for IBD and AMD treatments

GF-203 : Spore

  • Efficacy improved microbial therapeutics
  • Production of SOD and different MOA possessing effector molecules in the intestines.
    • Maximize therapeutic effects

GF-303 : EV

  • Extracellular Vesicle (EV)
  • SOD loaded extracellular vesicle (EV)
    • Respiratory therapeutics development in progress

Novel microbiome-enzyme drug candidate.

Safety, CoGs, Efficacy 인체입증, Delivery, Combination Safety, CoGs, Efficacy 인체입증, Delivery, Combination
아이콘
Safety
Pharmaceutical/food microorganism (GRAS)
derived drug candidate ensuring safety
아이콘
CoGs
Price competitiveness achieved by
securing enzyme/microbial
new drug production plant
아이콘
Efficacy
Clinical studies to pre-verify
beneficial effects on human,
enabling biomarker elucidation
아이콘
Delivery
Spore delivery
→ Gastric acid, bile acid, and protease resistant
Maximizing probiotic effect
아이콘
Combination
Combination of existing drugs
and therapeutic enzyme considering
each MOA to achieve synergistic effect